Galectin-3 ablation does not affect infarct size or inflammatory cytokines after experimental stroke in 24-month-old female mice

Oscar Manouchehrian\textsuperscript{a}, Emelie Andersson\textsuperscript{b}, Björn Eriksson-Hallberg\textsuperscript{a} and Tomas Deierborg\textsuperscript{a}

\textbf{Background} The tissue damage following a focal stroke causes an inflammatory response that is thought to aggravate the disease state. Galectin-3 is a proinflammatory molecule that has been shown to play a significant role in the inflammatory responses in brain diseases and following experimental stroke. In most animal experiments, young animals are used, although attempts are often made to model diseases that affect the elderly. Therefore, in this project, we intended to investigate the role of Galectin-3 in experimental stroke in older mice.

\textbf{Methods} In this project, 24-month-old (aged) female mice were subjected to an experimental stroke (permanent middle cerebral artery occlusion) 7 days before sacrifice. We wanted to investigate whether the absence of the inflammatory protein Galectin-3 could affect motor phenotype, neuroinflammation and infarct size. Number of mice without Galectin-3 (Galectin-3 KO) = 9, number of wildtype controls of the same age = 6.

\textbf{Results} In our aged female mice, we could not observe any significant differences between Galectin-3 KO and wildtype regarding the inclined plane test or cylinder test. We could not observe different infarct sizes between the two genotypes. In brain homogenates, we measured levels of 10 inflammatory cytokines, but we could not see any significant differences in any of them.

\textbf{Conclusion} In summary, it can be said that the absence of the inflammatory mediator Galectin-3 does not seem to have a strong poststroke effect in aged females. Unfortunately, we could not analyze these mice with immunohistochemistry, which limited our study.

\textbf{Keywords:} aging, behavior, cytokines, galectin-3, neurinflammation, pmcao, stroke, women

\textsuperscript{a}Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University and \textsuperscript{b}Department of Clinical Sciences, Clinical Memory Research Unit, Lund University, Lund, Sweden

Correspondence to Oscar Manouchehrian, Msc, Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, BMC B11, Lund University, Lund, Sweden
Tel: +46 46 222 08 66; e-mail: oscar.manouchehrian@med.lu.se

\textit{NeuroReport} 2022, 33:266–271

\textbf{Received} 14 December 2021 \textbf{Accepted} 20 February 2022

\textbf{Introduction}

Age is the most substantial nonmodifiable risk factor for ischemic stroke [1], and in the elderly, women are more affected than men [1]. Neuroinflammation mediated by microglia, the main innate immune cells of the central nervous system, has emerged as a key event in the pathophysiology of stroke disease. In response to the neuronal damage initially caused by deprivation of oxygen and essential nutrients, these cells are rapidly activated and recruited to the injury site [2]. The activated microglial cells express Galectin-3 [3], a \(\beta\)-galactosidase binding protein that has been suggested to play a significant role in regulating the inflammatory response [4] and the outcome after brain ischemia in experimental models [5,6]. For example, Lalancette-Hébert showed that the infarct lesion was increased in Galectin-3 null mice after transient middle cerebral artery occlusion (tMCAO) [5], while our group has shown that neuronal survival was higher after global ischemia [6]. However, these studies have been performed in young male mice, and it is not known how age or age combined with sex affects similar insults. Therefore, we aimed to measure the outcome after experimental stroke in aged female mice, with and without the expression of Galectin-3.

\textbf{Methods}

\textbf{Animals and surgery}

All proceedings and animal treatment were by the guidelines and requirements of the government committee on animal experimentation at Lund University (2012, Dnr: M427-12). Animals were housed in groups of 3–6 mice per cage under a 12:12 light-dark cycle with access to water and food ad libitum. In this study, we used female wildtype (\(n=6\)) and Galectin-3 knockout (\(n=9\)) C57BL/6J mice, aged 24 months. Galectin-3 KO mice were originally obtained for Dr. K. Sävman from Gothenburg University, where they were generated as...
Tubes were stored at −80°C. Glasses were dried and stored at −80°C.

were collected from approximately Bregma −2 to Bregma 5 and 6) were put in an Eppendorf tube each. Sections – 4 directly on glass. The remaining two sections (series 1 – 4) were put in a glass cylinder with a 90° angled mirror accounting for one ‘touch unit’, using a VLC media player.

Behavioral tests

Grip strength
The grip strength test was performed prior to and 6 days after pMCAO. The mouse was lowered over a metallic grid connected to a force sensor whereby it was allowed to attach to the grid with only its forelimbs. The mouse was then gently pulled back by its tail until the grip was released, and the displayed grip strength value was recorded. The grip strength of the left forelimb, right forelimb and both forelimbs was determined. For each condition, the mean value of three trials was calculated and used for analysis.

Inclined plane test
The inclined plane test was performed prior to and 6 days after pMCAO. Each mouse was placed head down on an inclined plane platform with a grooved plastic surface. The angle was gradually increased until the mouse was unable to hold its position. The last angle that the mouse was able to hold was recorded. Three rounds per mouse were performed and the mean angle was calculated and used for analysis.

Cylinder test
To assess for asymmetric use of forelimbs, the cylinder test [10] was performed 2 days after the pMCAO. Mice were put in a glass cylinder with a 90° angled mirror behind it for 3 min, and movements were recorded. Right and left forelimb use was analyzed as one weight-bearing contact with the glass wall accounting for one ‘touch unit’, using a VLC media player.

Cryosectioning
Animals were sacrificed on day 7 following surgery by isoflurane anesthesia and transcardial perfusion with PBS. Brains were then carefully removed and stored at −80 °C. Using a cryostat (Leica CM1905 S Cryostat, Wetzlar, Germany), a series of six 30 μm thick coronal brain sections was obtained, mounting sections in series 1–4 directly on glass. The remaining two sections (series 5 and 6) were put in an Eppendorf tube each. Sections were collected from approximately Bregma −2 to Bregma 2 (www.mbl.org). Glasses were dried and stored at −80°C. Tubes were stored at −80°C.

Morphology staining
Sections were fixed in paraformaldehyde (4%, Histolab Products AB, Gothenburg, Sweden) for 10 min and rinsed in PBS for 2 × 3 min. Sections were incubated in Mayers-HTX (Histolab) solution for 3 min and rinsed in a continuous flow of tap water for at least 5 min. Sections were incubated in eosin (Sigma-Aldrich, St Louis, Missouri, USA) for 1 min, and then rinsed in 70% ethanol (SOLVECO, Rosersberg, Sweden) for 1 min, followed by a rinse in 95% ethanol (SOLVECO) for 1 min and then rinsed in absolute ethanol (SOLVECO) for 2 × 1 min. Sections were incubated in HistoLab-Clear (HistoLab) for 3 × 1 min plus 1 min. Sections were mounted with Pertex (HistoLab) and air-dried on plastic, then stored at room temperature.

Infarct volume
The hematoxylin/eosin stainings were scanned, and image analysis was performed. Using ImageJ (https://imagej.nih.gov), whole coronal face areas of the contralateral hemisphere, the intact part of the ipsilateral hemisphere, and the entire ipsilateral hemisphere measured in all slides containing a distinguishable infarct (approximately responding to Bregma: 2 to −2 mm). Two infarct volumes, direct and indirect, were calculated. Direct volume was obtained by subtracting the intact ipsilateral area from the entire ipsilateral and indirect infarct area by subtracting the intact ipsilateral from the contralateral area.

Brain tissue homogenization
Every 5th and 6th slice at cryosectioning from whole brain tissue were frozen in −80 °C. Tissue mass weight was calculated for each tube. radioimmunoprecipitation assay (RIPA) buffer was prepared by adding one complete tablet (Roche, Basel, Switzerland) and one PhosStop (Roche) tablet to 10 mL of RIPA solution (Sigma-Aldrich). RIPA buffer was added in ratio 1 mL RIPA buffer/100 mg of brain tissue and stored on ice. Samples were manually homogenized using a plastic grinder. A sonicator (Branson, Ferguson, USA) was set on 10 s pulses with 60% amplitude and three pulses with 10-s intervals, and then stored on ice for a minimum of 30 min. Homogenized samples were centrifuged (Eppendorf Centrifuge 5430 R, Hamburg, Germany) on 10,000 rcf for 20 min. Supernatants were collected in Eppendorf tubes. Later, protein concentration was measured using a bicinchoninic acid (BCA) kit according to the manufacturer’s protocol (BCA Protein Assay-Kit, ThermoScientific, Sweden).

Cytokine assay
MesoScale plates were used to evaluate the cytokine levels (proinflammatory panels for IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 and tumor necrosis factor-α) from every whole brain homogenate (see in Brain tissue homogenization). Analyses were carried out according to the protocol provided by the manufacturer, as described before [11,12]. Samples were prepared by a 2-fold dilution of sample protein solution (containing 120 mg protein) in diluent 41.
### Statistical analysis
All statistical analyses were performed in GraphPad Prism 9 (GraphPad, San Diego, California, USA). *P* values ≤ 0.05 were considered significant. Since the wild-type group *N* was too low for normality testing, we used Mann-Whitney rank tests for pairwise comparisons. For some behavioral tests with more than one variable, we used 2-way analysis of variance (ANOVAs).

### Results

#### Behavioral tests
We first set out to study sensorimotor function in established experimental stroke tests previously used by us [13–16].

Grip strength with both front paws was decreased after pMCAO (Fig. 1a; 2-way ANOVA; *F*(1, 22) = 16.72; *P* = 0.0005), and interestingly, was overall lower in Galectin-3 KO females (Fig. 1a; 2-way ANOVA; *F*(1, 22) = 8.889; *P* = 0.0069). Furthermore, it was only in mice without Galectin-3 where grip strength was significantly lower after pMCAO (Fig. 1a; Sidak multiple comparison; *P* = 0.023). Grip strength with the injured (right) forepaw was not significantly weaker 6 days after pMCAO (Fig. 1b). In addition, there was no genotype difference with regards to right vs. left paw grip strength, 6 days after stroke (Fig. 1b).

Use of impaired forelimb after stroke was determined with the cylinder test. There was a nonsignificant trend of higher use of the impaired forelimb in the Galectin-3 KO mice (Fig. 2a; Mann–Whitney; *P* = 0.1447).

To further analyse limb motor function, we subjected the mice to an inclined plane test before and after pMCAO. We did not observe any differences regarding genotype or stroke (Fig. 2b; 2-way ANOVA). Taken together, we are not able to find a clear effect of Galectin-3 ablation on sensorimotor behavior following stroke.

#### Infarct volume
Infarct size was measured with a series of HTX slices. The absence of Galectin-3 did not significantly affect direct or indirect infarct volume 7 days after pMCAO in 24-month-old females (Fig. 3a,b; Mann–Whitney; *P* = 0.8639 and 0.3884, respectively).

#### Immunohistochemistry
We tried to label these brains with microglial markers, using multiple protocols, but we were not successful.

#### Cytokine expression
With a mesoscale U-plex Proinflammatory panel, we measured inflammatory cytokines from brain homogenates (from slices). Except for a few analytes (IFN-γ and IL12p70), we could read values within the detection range for all samples. Trends with lower expression in Galectin-3 KO could be seen for IL-1β and IL-6, but these differences were not statistically significant (Fig. 4b,f; Mann–Whitney; *P* = 0.18 and 0.0879, respectively).

---

**Fig. 1**

| Source of Variation | % of total variation | *P* value |
|--------------------|----------------------|-----------|
| Interaction        | 0.01526              | 0.9323    |
| Stroke             | 34.35                | 0.0005    |
| Genotype           | 18.37                | 0.0069    |

Grip strength. Wild-type *n* = 5 (one mouse did not grip with right forelimb), Galectin-3 KO *n* = 9. (a) Grip strength before and after pMCAO. (b) Grip strength with left and right (injured) front limb 6 days after pMCAO. 2-way ANOVA with Sidak multiple comparisons. Error bars SD, and exact *P*-values on top of comparison brackets. ANOVA, analysis of variance; pMCAO, permanent middle cerebral artery occlusion.
Likewise, levels of IFN-γ and IL-4 appeared higher in KO females, but differences were not statistically significant (Fig. 4a,d; Mann–Whitney; \( P = 0.2284 \) and \( P = 0.1135 \), respectively).

**Discussion**

Many experimental studies show that neuroinflammation after cerebral focal ischemia can exacerbate the insult [17]. However, most studies have been performed in adolescent mice when modeling these stroke-related diseases that usually affect the elderly [18]. Galectin-3 is an inflammatory mediator that has been implicated in many diseases, including brain ischemia. In some conditions, it exerts protective and antiapoptotic effects [5], and in others, it exacerbates inflammation and injury [6,19]. Our group has previously shown that Galectin-3 ablation improves outcomes in experimental models of neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease [6,8,20]. In this study, we subjected 24-month-old female mice to pMCAO. In contrast to a previous study by Lalancette-Hébert et al. (2012), we do not report differences in lesion size between the genotypes [5]. Of course, discrepancies between our observations and Lalancette-Hébert were not only limited to the age and sex of the mice but could also be related to differences in the stroke model (permanent versus transient) and duration (7 days and 72 h) [5]. Our study design enabled us to perform several behavioral tests, and we did detect a significant genotype effect in grip strength with both front paws, where Galectin-3 ablated females were weaker. Both genotypes were weaker after stroke, but Galectin-3 KO mice were weaker before and decreased more after the pMCAO surgery. In the grip strength test with only one paw and the inclined plane test, we could not detect any effect regarding either genotype or injury/stroke.

Our study is narrow in its scope and the lowered power due to the relatively small control group may have
resulted in nondetection of significant differences. In addition, it is possible that our cytokine results were diluted when we homogenized both the ipsilateral and the ‘healthy’ contralateral hemispheres into one sample. Moreover, we do not have a young group of mice, or any males, for comparisons to our aged female results. Initially, we aimed at having both female and male mice, but due to males killing one another in the home cages, we were only able to focus this study on female mice. Because publications including female mice are underrepresented in the primary literature, we believe that this study is important to be made available. In fact, females are especially vulnerable to stroke disease, likely related to decreasing levels of estrogen [21,22]. It is difficult to say whether the results in aged male Galectin-3 null mice would have differed from male wild-type controls, but

Inflammatory cytokines in whole brain homogenates. Wildtype \( n=6 \), Galectin-3 KO \( n=9 \). (a) IFN-\( \gamma \). Here one Galectin-3 KO sample was below the detection range. (b) IL-1\( \beta \), (c) IL-2, (d) IL-4, (e) IL-5, (f) IL-6, (g) IL-10 (h) IL-12p70. One wildtype sample was below detection range (i) KC/GRO, (j) TNF-\( \alpha \). Mann–Whitney test is used for pairwise comparison. Error bars= min/max, and exact \( P \) value on top of comparison bracket. TNF, tumor necrosis factor.
because the inflammatory response differs between the sexes [21], the outcome is not guaranteed to be similar to our findings.

In conclusion, the ablation of Galectin-3 did not affect infarct size and levels of brain cytokines in aged female mice. However, Galectin-3 null mice appeared to be a bit weaker in grip strength, both before and after stroke. How this relates to outcomes in human patients is not easy to decipher. But we would suggest that researchers in future studies concerning diseases of primarily aged women take age and sex into consideration when designing their experiments.

Acknowledgements
We were funded by the Strategic Research Area MultiPark (Multidisciplinary Research in neurodegenerative diseases) at Lund University, the Swedish Alzheimer Foundation, the Parkinson Foundation, the Swedish Dementia Association, G&J Kock Foundation, Olle Engkvist Foundation, the Swedish Brain Foundation, and STROKE-Riksförbundet.

Conflicts of interest
There are no conflicts of interest.

References
1 Roy-O’Reilly M, McCullough LD. Age and sex are critical factors in ischemic stroke pathology. Endocrinology 2018; 159:3120–3131.
2 Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17:796–808.
3 Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 2007; 27:2996–2605.
4 Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9:338–352.
5 Lalancette-Hébert M, Swamp U, Beaulieu JM, Bohacek I, Abdelhamid E, Weng YC, et al. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J Neurosci 2012; 32:10383–10395.
6 Burguillos MA, Svensson M, Schulte T, Boza-Serrano A, Garcia-Quintanilla A, Kavanagh E, et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep 2015; 10:1626–1635.
7 Colnot C, Fowlis D, Ripoche MA, Bouchaert I, Poirier F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn 1998; 211:306–313.
8 Boza-Serrano A, Ruiz R, Sanchez-Varo R, Garcia-Revilla J, Yang Y, Jimenez-Ferrer I, et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol 2019; 138:251–273.
9 Clausen BH, Lundberg L, Yli-Karjanmaa M, Martin NA, Svensson M, Alfsen MZ, et al. Fumarate decreases edema volume and improves functional outcome after experimental stroke. Exp Neurol 2017; 295:144–154.
10 Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user’s guide. Nat Rev Neurosci 2009; 10:519–528.
11 Svensson M, Andersson E, Manouchehrian O, Yang Y, Deierborg T. Voluntary running does not reduce neuroinflammation or improve non-cognitive behavior in the 5xFAD mouse model of Alzheimer’s disease. Scien 2020; 10:1346.
12 Manouchehrian O, Ramos M, Bachiller S, Lundgaard I, Deierborg T. Acute systemic LPS-exposure impairs perivascular CSF distribution in mice. J Neuroinflammation 2021; 18:34.
13 Clausen BH, Lambertsen KL, Dagnæs-Hansen F, Babcock AA, von Linstow CU, Meldgaard M, et al. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol 2016; 131:775–791.
14 Inacio AR, Liu Y, Clausen BH, Svensson M, Kucharcz K, Yang Y, et al. Endogenous IFN-γ signaling exerts anti-inflammatory actions in experimentally induced focal cerebral ischemia. J Neuroinflammation 2015; 12:211.
15 Clausen BH, Degr M, Sivasaravanapanar M, Fogtmann T, Andersen MG, Trojanowski MD, et al. Conditional ablation of myeloid TNF increases lesion volume after experimental stroke in mice, possibly via altered ERK1/2 signaling. Sci Rep 2016; 6:29291.
16 Madsen PM, Clausen BH, Degr M, Thyssen S, Kristensen LK, Svensson M, et al. Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia. J Cereb Blood Flow Metab 2016; 36:1553–1569.
17 Szepesi Z, Manouchehrian O, Bachiller S, Deierborg T. Bidirectional microglia-neuron communication in health and disease. Front Cell Neurosci 2018; 12:323.
18 Manwani B, Friedler B, Verma R, Venna VR, McCullough LD, Liu F. Perfusion of ischemic brain in young and aged animals: a laser speckle flowmetry study. Stroke 2014; 45:571–578.
19 Manouchehrian O, Amér K, Deierborg T, Taylor L. Who let the dogs out?: detrimental role of Galectin-3 in hyperperfusion-induced retinal degeneration. J Neuroinflammation 2015; 12:92.
20 Boza-Serrano A, Reyes JF, Rey NL, Leffler H, Bousslet L, Nilsson U, et al. The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol Commun 2014; 2:156.
21 Liu F, Yuan R, Benashski SE, McCullough LD. Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab 2009; 29:792–802.
22 Manwani B, Liu F, Santeron V, Hammond MD, Singson LH, McCullough LD. Differential effects of aging and sex on stroke induced inflammation across the lifespan. Exp Neurol 2013; 249:120–131.